InMed Pharmaceuticals Inc (INM)

[NetworkNewsWire]

IMLFF Teams with Pharmaseed to Advance Development of INM-750

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into an agreement with Pharmaseed Ltd., Israel’s largest GLP-certified pre-clinical contract research organization. Under the terms of this agreement, the Pharmaseed development team will now play a key role in the ongoing development of InMed’s lead compound, INM-750, which is a proprietary, topical cannabinoid product candidate that’s currently being studied as a therapy in epidermolysis bullosa and other potential dermatological and wound-healing applications. “This agreement with Pharmaseed now adds one of Israel’s leading formulation development teams to our efforts and represents an important strategic relationship as we move INM-750 towards our first clinical trial,” Eric A. Adams, CEO of InMed, noted in the news release. Moving forward, Pharmaseed will be tasked with developing a final formulation of INM-750 for continued R&D efforts, including IND-enabling pharmacology and toxicology studies, as well as subsequent clinical studies.

To view the full press release, visit http://nnw.fm/hF9pC

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.